Life Molecular Imaging Expands Neuraceq® Availability Through Strategic Partnership in Salt Lake City
Life Molecular Imaging (LMI), in collaboration with PharmaLogic Holdings Corp., has recently announced the extension of Neuraceq® availability through a strategic partnership aimed at enhancing patient access to essential diagnostic imaging. This development took place at PharmaLogic's radiopharmaceutical manufacturing facility located near Salt Lake City, Utah, where the first commercial doses of Neuraceq® were produced and made available as of April 23, 2025.
Neuraceq® is a radioactive diagnostic agent that has received FDA approval for the identification of amyloid plaques in the brains of adult patients who exhibit signs of cognitive impairment. This tool is critical in the evaluation of Alzheimer's disease and other forms of cognitive decline, as it can significantly influence treatment decisions and eligibility for clinical trials regarding new anti-amyloid therapies.
The expansion of Neuraceq® represents a significant step forward in making advanced imaging solutions more readily available to healthcare providers and patients alike. Colleen Ruby, the US Country Head and Chief Operating Officer for LMI, expressed enthusiasm about enhancing accessibility in this essential region. 'This expansion reflects LMI’s commitment to ensuring broad accessibility to Neuraceq®, reinforcing our dedication to supporting a key step on the pathway to treatment,' Ruby stated.
Neuraceq® (florbetaben 18F) is an adjunctive tool designed for Positron Emission Tomography (PET) imaging, which estimates the density of β-amyloid neuritic plaques in adult patients experiencing cognitive decline evaluation. Understanding the level of amyloid plaques can help differentiate between Alzheimer’s disease and various other neurological conditions.
The importance of a negative Neuraceq scan is particularly noteworthy; it suggests sparse to no neuritic plaques, thereby reducing the likelihood of a neuropathological diagnosis of Alzheimer’s. However, a positive scan indicates moderate to frequent presence of these plaques, typically associated with Alzheimer’s but also present in older individuals with normal cognitive function and other neurological conditions.
It's crucial to note that while Neuraceq® can deliver invaluable insights, it does not, by itself, establish a diagnosis of Alzheimer’s or any other cognitive disorder. Furthermore, there are safety considerations related to its use; potential risks include image interpretation errors and the inherent radiation exposure associated with radiopharmaceuticals. Patients and healthcare workers should be mindful of their overall exposure to minimize related risks.
The introduction of Neuraceq® is viewed as a positive advancement in patient care within the intricate landscape of diagnostic imaging for neurodegenerative diseases. As LMI continues to lead in the development and distribution of innovative PET radiopharmaceuticals, they remain focused on improving early detection methods, leading to better therapeutic outcomes and enhanced quality of life for patients.
Life Molecular Imaging, headquartered in Boston, operates with a mission to pioneer novel PET products targeting chronic and life-threatening diseases. This commitment not only reflects their dedication to patient care but also signifies a broader scope of progress within the medical imaging field. As they push forward with innovative solutions like Neuraceq®, the landscape of neurodegenerative disease evaluation is set to evolve, providing healthcare professionals with better tools to assist their patients effectively.
In this context, the release of Neuraceq® in Salt Lake City is a pivotal milestone, ensuring that advanced diagnostic options are not just available, but also optimally distributed to meet the urgent needs of the community. This augmentation in availability signifies LMI’s dedication to provider access, ultimately improving the standard of care delivered to patients undergoing assessments for Alzheimer’s disease and other cognitive impairments.
To learn more about Neuraceq® and its implications for patient care, please visit https://neuraceq.com.
Neuraceq® is a radioactive diagnostic agent that has received FDA approval for the identification of amyloid plaques in the brains of adult patients who exhibit signs of cognitive impairment. This tool is critical in the evaluation of Alzheimer's disease and other forms of cognitive decline, as it can significantly influence treatment decisions and eligibility for clinical trials regarding new anti-amyloid therapies.
The expansion of Neuraceq® represents a significant step forward in making advanced imaging solutions more readily available to healthcare providers and patients alike. Colleen Ruby, the US Country Head and Chief Operating Officer for LMI, expressed enthusiasm about enhancing accessibility in this essential region. 'This expansion reflects LMI’s commitment to ensuring broad accessibility to Neuraceq®, reinforcing our dedication to supporting a key step on the pathway to treatment,' Ruby stated.
Neuraceq® (florbetaben 18F) is an adjunctive tool designed for Positron Emission Tomography (PET) imaging, which estimates the density of β-amyloid neuritic plaques in adult patients experiencing cognitive decline evaluation. Understanding the level of amyloid plaques can help differentiate between Alzheimer’s disease and various other neurological conditions.
The importance of a negative Neuraceq scan is particularly noteworthy; it suggests sparse to no neuritic plaques, thereby reducing the likelihood of a neuropathological diagnosis of Alzheimer’s. However, a positive scan indicates moderate to frequent presence of these plaques, typically associated with Alzheimer’s but also present in older individuals with normal cognitive function and other neurological conditions.
It's crucial to note that while Neuraceq® can deliver invaluable insights, it does not, by itself, establish a diagnosis of Alzheimer’s or any other cognitive disorder. Furthermore, there are safety considerations related to its use; potential risks include image interpretation errors and the inherent radiation exposure associated with radiopharmaceuticals. Patients and healthcare workers should be mindful of their overall exposure to minimize related risks.
The introduction of Neuraceq® is viewed as a positive advancement in patient care within the intricate landscape of diagnostic imaging for neurodegenerative diseases. As LMI continues to lead in the development and distribution of innovative PET radiopharmaceuticals, they remain focused on improving early detection methods, leading to better therapeutic outcomes and enhanced quality of life for patients.
Life Molecular Imaging, headquartered in Boston, operates with a mission to pioneer novel PET products targeting chronic and life-threatening diseases. This commitment not only reflects their dedication to patient care but also signifies a broader scope of progress within the medical imaging field. As they push forward with innovative solutions like Neuraceq®, the landscape of neurodegenerative disease evaluation is set to evolve, providing healthcare professionals with better tools to assist their patients effectively.
In this context, the release of Neuraceq® in Salt Lake City is a pivotal milestone, ensuring that advanced diagnostic options are not just available, but also optimally distributed to meet the urgent needs of the community. This augmentation in availability signifies LMI’s dedication to provider access, ultimately improving the standard of care delivered to patients undergoing assessments for Alzheimer’s disease and other cognitive impairments.
To learn more about Neuraceq® and its implications for patient care, please visit https://neuraceq.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.